Twist Bioscience Corporation
TWST
Rank in Stocks
#2144
Twist Bioscience Corporation operates as a leading synthetic biology firm,... Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.
Share Price
$144.87
Market Cap
$9.54B
Change (1 day)
3.65%
Change (1 year)
342.47%
Country
US
Trade Twist Bioscience Corporation (TWST)
Category
Healthcare
Revenue for Twist Bioscience Corporation (TWST)
Revenue in Jun 2026 TTM: $431.80M
According to Twist Bioscience Corporation latest financial reports the company's current revenue (TTM) is $431.80M. In 2024 the company made a revenue of $312.97M an increase over the revenue in the year 2023 that was $245.11M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Twist Bioscience Corporation from 2016 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2026 (TTM) | $431.80M | 14.67% |
| 2025 | $376.57M | 20.32% |
| 2024 | $312.97M | 27.69% |
| 2023 | $245.11M | 20.41% |
| 2022 | $203.57M | 53.83% |
| 2021 | $132.33M | 46.87% |
| 2020 | $90.10M | 65.67% |
| 2019 | $54.39M | 113.89% |
| 2018 | $25.43M | 136.16% |
| 2017 | $10.77M | 374.53% |
| 2016 | $2.27M | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| $46.34B | 10,630.94% |
US
|
|
| $25.11B | 5,714.52% |
US
|
|
| $2.71B | 526.93% |
US
|
|
| - | - |
CN
|
|
| $7.37B | 1,607.28% |
US
|
